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Abstract Vascular endothelial growth factor (VEGF) produc-
tion was analysed in megakaryocytic cell lines and CD34+
haematopoietic progenitors following treatment with thrombo-
poietin (TPO). In CMK cells TPO caused a time- and dose-
dependent increase in the levels of VEGF released into the
medium. A similar effect was observed in UT-7/mpl cells
transfected with the TPO receptor c-Mpl, but not in parental
UT-7 cells. In CD34+ haematopoietic progenitor cell cultures
TPO stimulated VEGF mRNA expression and VEGF protein
release. Production of VEGF in CD34+ cultures increased with
TPO-induced megakaryocytic differentiation, but not with
erythroid or myelomonocytic differentiation induced respectively
by erythropoietin and granulocyte-macrophage colony-stimulat-
ing factor. These results demonstrate that TPO stimulates
VEGF release in c-Mpl-expressing cells and suggest that this
process is an integral feature of the megakaryocytic differentia-
tion programme.
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1. Introduction
Vascular endothelial growth factor (VEGF), also known as
vascular permeability factor, is a potent angiogenic molecule
in vivo and an endothelial cell-speci¢c mitogen in vitro (re-
viewed in [1]). It also promotes increased vascular permeabil-
ity [2] and migration of monocytes through endothelial layers
[3]. VEGF plays a major role in the development of blood
vessels during embryogenesis [4], and in the neovascularisa-
tion of solid tumours [5,6]. In addition, VEGF has been im-
plicated in wound healing [7] and in pathological conditions
such as diabetic retinopathy [8], rheumatoid arthritis [9] and
atherosclerosis [10].
VEGF is a homodimeric glycoprotein with structural ho-
mology to platelet-derived growth factor. Four isoforms of
human VEGF, arising from alternative splicing of a single
gene, have been identi¢ed [11]. All isoforms have a peptide
leader sequence that promotes their active secretion. The two
smaller species, VEGF121 and VEGF165, are freely soluble,
whereas the two larger ones, VEGF189 and VEGF206, are
found bound to the cell surface or the extracellular matrix.
VEGF was shown to be produced constitutively by tumour
cell lines of various origins [12]. In addition, it is strongly
induced by hypoxia, both in transformed [13] and in non-
transformed cells [14^16]. Furthermore, in a number of cell
types several growth factors and cytokines, including platelet-
derived growth factor BB, basic ¢broblast growth factor,
transforming growth factor-L, interleukin-1L, interleukin-6,
tumour necrosis factor-K and interferon-L, have been shown
to induce VEGF expression to varying degrees [15,17^21].
Recently, Mohle and his colleagues have reported that
VEGF is produced constitutively by human mature megakar-
yocytes (MKs) [22]. MKs are generated in the bone marrow
by a complex di¡erentiation process that is controlled primar-
ily by the hormone thrombopoietin (TPO) (reviewed in [23]).
In this study, we investigated the possibility that TPO might
also stimulate VEGF production. We demonstrate that TPO
causes a marked increase of VEGF release in cell lines that
express the TPO receptor c-Mpl. Furthermore, we show that
in vitro, production of VEGF by haematopoietic progenitor
cells is speci¢cally associated with TPO-induced di¡erentia-
tion, and not with the di¡erentiating e¡ects of other similarly
acting cytokines.
2. Materials and methods
2.1. Materials
Recombinant human TPO, granulocyte-macrophage colony-stimu-
lating factor (GM-CSF), erythropoietin (EPO) and the human VEGF
enzyme-linked immunoabsorbent assay kit were purchased from RpD
Systems (Abingdon, UK). Tissue culture media and additives were
from Gibco Life Technologies (Paisley, UK). Other reagents were
from standard suppliers or as listed in the text.
2.2. Cell culture
The human megakaryocytic cell line CMK was maintained in
RPMI supplemented with 10% fetal calf serum (FCS), 0.1 mg/ml
streptomycin, 100 U/ml penicillin and 0.25 Wg/ml amphotericin B.
The growth factor-dependent pluripotent haematopoietic cell line
UT-7 was maintained in K-minimum essential medium without deox-
yribonucleosides, supplemented with 2 mM L-glutamine, 10% FCS,
2.5 ng/ml GM-CSF and the above antibiotics. UT-7 cells transfected
with a human c-mpl cDNA (UT-7/mpl) [24] were kindly supplied by
Prof. W. Vainchenker (Institut Gustave Roussy, Villejuif, France) and
maintained under the same conditions as parental UT-7 cells except
that the medium contained 0.5 mg/ml G418. Cultures were kept in
exponential growth (2^7U105 cells/ml) at 37‡C in a humidi¢ed incu-
bator under 5% CO2/95% air. For experiments, prior to stimulation,
cells were rendered quiescent by incubation for 18 h in their respective
media containing either 0.5% FCS (CMK), or lacking GM-CSF (UT-
7 and UT-7/mpl), as previously described [25]. After washing, cells
were resuspended in their respective fresh quiescence media at 5^
6U105 cells/ml. To induce VEGF release, quiescent cells were incu-
bated for 24 h (unless otherwise indicated) with haematopoietic
growth factors as described in the respective legends to ¢gures. At
the end of the incubation cell count and viability were determined by
FEBS 19824 17-2-98
0014-5793/98/$19.00 ß 1998 Federation of European Biochemical Societies. All rights reserved.
PII S 0 0 1 4 - 5 7 9 3 ( 9 8 ) 0 0 0 5 6 - 8
*Corresponding author. Fax: (44) (171) 813 2846.
E-mail: j.erusalimsky@ucl.ac.uk
1Permanent address: Department of Animal Physiology,
Jagiellonian University, Ingardena 6, 30-060 Cracow, Poland.
FEBS 19824FEBS Letters 423 (1998) 10^14
the trypan blue dye exclusion method. Cell viability remained above
85% at all culture conditions. Supernatants for measuring VEGF
concentration were recovered after centrifugation at 1000Ug for 10
min at 20‡C.
CD34 haematopoietic progenitor cells were isolated from umbil-
ical cord blood by magnetic immunoselection, using the anti-CD34
monoclonal antibody (mAb) QBEND/10 and super-paramagnetic Mi-
croBeads (Miltenyi Biotec Ltd, Camberley, UK) as previously de-
scribed [26]. Following puri¢cation, CD34 cells (95^98% purity)
were cultured in Iscove’s modi¢ed Dulbecco’s medium supplemented
with 0.1 mM minimum essential amino acids, 100 U/ml penicillin, 0.1
mg/ml streptomycin, 2 mM glutamine, 1 mM sodium pyruvate, 2 mg/
ml L-asparagine, 0.2% bovine serum albumin (BSA), and 10% human
cord blood platelet-poor plasma, in the presence or absence of di¡er-
ent haematopoietic growth factors as indicated in the respective
legends to ¢gures. Cells were grown in 24-well tissue culture plates
(Falcon) at 37‡C in a humidi¢ed incubator under 5% CO2/95% air,
for various lengths of time. At the end of the culture period cell count
and viability were determined as described above. In all the cultures
containing haematopoietic growth factors viability remained above
95%. Supernatants for measuring VEGF concentration were recov-
ered after centrifugation at 400Ug for 5 min at 4‡C. Cell pellets
were saved for £ow cytometric analysis or for reverse transcriptase-
polymerase chain reaction (RT-PCR) analysis.
2.3. Determination of VEGF release
The VEGF concentration in cell supernatants was measured using
an enzyme-linked immunoabsorbent assay (Quantikine, RpD Sys-
tems) that recognises human VEGF121 and VEGF165. The lower limit
of VEGF detection in this assay was 3.0 pg/ml. Assays were per-
formed in duplicate and the results averaged.
2.4. Flow cytometric analysis of antigen expression
Phenotypic di¡erentiation of CD34 progenitor cell cultures was
monitored by £ow cytometry using the following £uorescein isothio-
cyanate (FITC)-conjugated mAb: Y2/51 (Dako, UK), which detects
the megakaryocytic lineage-speci¢c antigen CD61 (glycoprotein IIIa);
CLB-143 (CLB, Amsterdam, The Netherlands), which recognises the
erythroid di¡erentiation marker glycophorin A; and Leu-M3 (Becton
Dickinson, UK), which detects the antigen CD14 on myelomonocytic
cells. Cells (1^2U106) were stained with saturating amounts of FITC-
mAb in 0.1 ml Dulbecco’s phosphate-bu¡ered saline (PBS)/1% BSA
for 30 min at 4‡C. Subsequently, the cells were washed once with PBS/
BSA, resuspended in 0.5 ml, and ¢nally analysed by £ow cytometry
using a FACScan instrument and Lysis II software (Becton Dickin-
son, Mountain View, CA, USA). Light-scatter parameters were used
to exclude dead cells. The boundary between antigen-positive and
-negative cells was determined according to the £uorescence distribu-
tion of cells stained with an FITC-conjugated isotype-matched control
antibody.
2.5. Puri¢cation of CD61+ cells
CD61 cells were puri¢ed by magnetic immunoselection from
CD34 cultures grown for 9 days in the presence of TPO, using
FITC-Y2/51 and an anti-FITC mAb coupled to MicroBeads (Miltenyi
Biotec Ltd). Brie£y, following addition of 1 ng/ml prostaglandin I2,
2.5^3.0U106 cells were harvested by centrifugation at 300Ug for 10
min, stained with FITC-Y2/51 (1:20 dilution) as described above, and
washed once with PBS containing 0.5% BSA and 2 mM EDTA
(PBE). Cells were subsequently incubated with anti-FITC MicroBeads
(1:10 dilution) in 0.1 ml PBE for 15 min at 4‡C, washed once, resus-
pended in 0.5 ml PBE, and ¢nally loaded onto a Large Cells Separa-
tion Column Type MS (Miltenyi Biotec Ltd). The column was washed
with PBE as described by the manufacturer and CD61 cells were
eluted in 1 ml culture medium with a purity of 98%.
2.6. Reverse transcriptase-polymerase chain reaction analysis of RNA
Cell pellets harvested from CD34 cultures were washed twice with
ice-cold PBS and total cellular RNA extracted according to the acid
guanidinium thiocyanate/phenol/chloroform method [27]. RT-PCR
analysis was performed as described by Stavri et al. [15] using speci¢c
VEGF and L-actin primers. Aliquots of the PCR reactions were sep-
arated on 1.5% agarose gels. VEGF PCR products were identi¢ed by
Southern blot analysis using a murine 32P-labelled VEGF164 cDNA
probe [28].
2.7. Statistical analysis
Experiments were performed at least twice and unless otherwise
stated results from one representative experiment are shown. Where
indicated, levels of statistical signi¢cance for VEGF release data were
determined using the Student’s t-test.
3. Results
3.1. TPO enhances VEGF release in CMK cells
The e¡ect of TPO on VEGF production was initially exam-
ined in CMK cells (Fig. 1). This megakaryocytic cell line was
chosen because it had been previously reported to display a
functional response to TPO [29]. Quiescent cells released con-
stitutively low amounts of VEGF (Fig. 1A, open circles). Ad-
dition of 20 ng/ml TPO resulted in a marked time-dependent
increase in the level of VEGF accumulated in the medium
(Fig. 1A, closed circles). This level increased sharply for ap-
proximately 12 h and thereafter continued to rise at a slower
rate. The TPO-stimulated release of VEGF was also dose-
dependent, with a maximal e¡ect (9-fold increase) observed
at 10 ng/ml TPO (Fig. 1B).
3.2. The stimulation of VEGF release by TPO is mediated by
c-Mpl
The receptor for TPO, a member of the cytokine receptor
superfamily, is encoded by the proto-oncogene c-mpl [30]. To
con¢rm that this receptor mediates the TPO-stimulated re-
lease of VEGF, we compared the haematopoietic cell line
UT-7/mpl, which expresses a transfected c-mpl [25], with its
parental counterpart UT-7; the latter does not express the
endogenous gene in su⁄cient amounts to elicit a functional
response to TPO [25]. As shown in Fig. 2, TPO was unable to
stimulate the release of VEGF in parental UT-7 cells. In con-
trast, in UT-7/mpl cells a dose-dependent e¡ect was observed.
UT-7 cells express functional receptors for EPO and GM-
CSF [31], which also belong to the cytokine receptor super-
family. Therefore, the ability of these haematopoietic growth
factors to stimulate the release of VEGF was examined for
comparison (Fig. 2). EPO had no signi¢cant e¡ect in either
parental or c-mpl-transfected UT-7 cells. In contrast, GM-
CSF stimulated a signi¢cant release of VEGF in both cell
lines. In this case the magnitude of the response was similar
to that observed in UT-7/mpl cells following treatment with
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Fig. 1. Stimulation of VEGF release by TPO in CMK cells. Quies-
cent CMK cells were incubated (A) for various lengths of time in
the presence or absence of 20 ng/ml TPO or (B) for 24 h with dif-
ferent concentrations of TPO. The amount of VEGF released into
the medium was measured as described in Section 2. Cell numbers
did not change signi¢cantly during the course of the incubation pe-
riods. Values represent the mean þ S.D. from replicate determina-
tions.
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TPO (Fig. 2). These results con¢rmed that it is the absence of
functional c-Mpl receptors that was responsible for the failure
of TPO to stimulate the release of VEGF in parental UT-7
cells.
3.3. TPO induces VEGF mRNA expression and VEGF protein
release in liquid cultures of CD34+ cells
Since VEGF secretion is a common feature of transformed
cells, it was important to establish that TPO can stimulate
VEGF production also in non-transformed cells. For this pur-
pose we isolated CD34 normal human haematopoietic pro-
genitors from umbilical cord blood. Semi-quantitative PCR
analysis of VEGF mRNA showed that treatment of these cells
with 20 ng/ml TPO for 24 h resulted in a marked increase of
two PCR products of 563 bp and 431 bp, which correspond
respectively to the sizes expected for VEGF165 and VEGF121
(Fig. 3). These VEGF isoforms have been shown to be readily
secreted by producer cells [11]. VEGF transcripts encoding the
larger cell-associated isoforms were not detected.
In agreement with previous studies [32], Fig. 4 shows that
treatment of CD34 cells with TPO in liquid culture resulted
in a time-dependent increase in the number of cells expressing
the megakaryocytic di¡erentiation marker CD61 (Fig. 4, open
diamonds). The increase in the number of megakaryocytic
cells was clearly evident after 4 days in culture and continued
for at least 12 days. Furthermore, consonant with the in-
duction of mRNA for the secreted forms of VEGF (Fig. 3),
incubation with TPO also resulted in a time-dependent
increase of VEGF protein in the culture medium (Fig. 4,
open circles). Under our experimental conditions, however,
a substantial rise in the level of VEGF protein was detectable
only after 1 week incubation. Thereafter, VEGF levels
increased at a faster rate, following closely the increase in
the number of CD61 megakaryocytic cells. Addition of a
second dose of TPO after 8 days resulted in a more rapid
accumulation of megakaryocytic cells (Fig. 4, closed dia-
monds). Similarly, a faster increase in the rate of VEGF ac-
cumulation was also observed in this case (Fig. 4, closed
circles). Thus, the increase in TPO-stimulated release of
VEGF appeared to correlate with the increase in the number
of megakaryocytic cells.
3.4. VEGF production correlates with megakaryocytic
di¡erentiation
The results described above suggested that the TPO-stimu-
lated release of VEGF was associated with TPO induction of
megakaryocytic di¡erentiation. On the other hand it could be
argued that the time-dependent rise of VEGF levels in culture
supernatants was unrelated to the di¡erentiation e¡ects of
TPO, and resulted merely from the increase in cell number.
To distinguish between these two possibilities we examined
the e¡ects of other haematopoietic growth factors on the stim-
ulation of VEGF release. Fig. 5A shows that incubation of
CD34 cells for 9 days with either GM-CSF, EPO or TPO
caused similar increases in the number of cells. However, only
TPO induced megakaryocytic di¡erentiation (Fig. 5B). In con-
trast, in the presence of EPO 65% of cells became positive for
the erythroid marker glycophorin A, and in the presence of
GM-CSF 35% were positively stained for myelomonocytic
di¡erentiation marker CD14 (data not shown). Furthermore,
as shown in Fig. 5C, only TPO was able to stimulate a sig-
ni¢cant rise in VEGF levels. Thus, while all three factors,
induced similar increases in the number of cells, only TPO,
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Fig. 4. Stimulation of VEGF release and megakaryocytic di¡erentia-
tion by TPO in CD34 progenitor cell cultures. CD34 cells were
plated at 2.5U105 cells/ml and cultured in the presence of 20 ng/ml
TPO for 12 days (open symbols). Parallel cultures were given a sec-
ond dose of TPO at day 8 (closed symbols). The number of CD61
cells and the amount of VEGF released into the medium was deter-
mined every 2 days as described in Section 2.
Fig. 3. Characterisation of VEGF transcripts upregulated by TPO
in CD34 progenitor cells. CD34 cells were plated at 2.4U106
cells/ml and incubated with or without 20 ng/ml TPO for 24 h. To-
tal cellular RNA was prepared from 1.2U106 cells and then ana-
lysed by RT-PCR. VEGF cDNA ampli¢cation products were visual-
ised by Southern blot analysis using a 32P-labelled VEGF164 cDNA
probe. L-Actin cDNA ampli¢cation was visualised by direct staining
of the agarose gel with ethidium bromide.
Fig. 2. Stimulation of VEGF release by haematopoietic growth fac-
tors in UT-7 cells. (A) Parental and (B) c-Mpl-expressing quiescent
UT-7 cells were incubated for 24 h with 5 or 40 ng/ml TPO, 2 ng/
ml GM-CSF or 2 U/ml EPO, as indicated. The level of VEGF re-
leased into the medium was determined as described in Section 2
and is expressed relative to the level in non-stimulated cells (control)
incubated in parallel. Values represent the mean þ S.E. of three
(UT-7) or eight (UT-7/mpl) experiments. In the case of UT-7/mpl,
results obtained with two di¡erent clones (four experiments per
clone) were pooled and averaged. *P6 0.05; **P6 0.01.
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which induced megakaryocytic di¡erentiation, stimulated the
release of VEGF in these cultures.
3.5. VEGF is released from megakaryocytic cells
In order to con¢rm that the VEGF released into the culture
medium originated directly from megakaryocytic cells, CD61
cells were puri¢ed by magnetic immunoselection from CD34
cultures grown for 9 days in the presence of TPO. Fig. 6
shows that when puri¢ed CD61 cells were subcultured for
a further 3 days, measurable levels of VEGF were detected in
the medium. Furthermore, in the presence of TPO the levels
of VEGF increased by 3-fold (Fig. 6). In contrast, VEGF was
not detected in cultures of CD613 cells incubated in parallel
(data not shown). Thus, TPO stimulated the release of VEGF
straight from cells of the megakaryocytic lineage.
4. Discussion
In vivo, TPO is the major regulator of megakaryocytopoi-
esis and platelet production [23,33]. In vitro, TPO can stim-
ulate the proliferation of MK progenitor cells and promote
MK terminal di¡erentiation [29,32]. The present study dem-
onstrates a novel action of TPO, the stimulation of VEGF
production in cells that express the TPO receptor c-Mpl.
Recently, Mohle et al. reported that the megakaryocytic cell
line DAMI as well as ex vivo generated mature MK produce
VEGF constitutively [22]. These workers also reported that
TPO increased the secretion of VEGF in mature MKs, but
in contrast to our study, they did not investigate this e¡ect of
TPO in cell lines or in immature haematopoietic cells under-
going di¡erentiation in vitro. Furthermore, they showed that
thrombin, which has a di¡erent physiological role and mode
of action, also stimulated VEGF secretion. Thus, the signi¢-
cance of Mohle’s ¢ndings with regard to the mechanism of
action and biological role of TPO remained unclear.
In this work we found that TPO stimulates the release of
VEGF in c-mpl-transfected UT-7 cells and also in CMK cells;
the latter expresses a functional TPO receptor from the en-
dogenous gene. Thus, this e¡ect of TPO cannot be attributed
to an artefact of the transfection, or to a property of one
particular cell line. Furthermore, the doses of TPO required
to stimulate the release of VEGF in these cells were compar-
able to those reported to stimulate c-Mpl-mediated signalling
events and functional responses. Taken together these ¢ndings
demonstrate that engagement of the c-Mpl receptor by TPO
leads to the induction of VEGF release.
A major ¢nding of the present study is that TPO induced
both VEGF mRNA expression and protein release from nor-
mal human haematopoietic progenitor cells undergoing di¡er-
entiation in liquid culture. In these cells the e¡ect was selective
for TPO as EPO and GM-CSF, two other haematopoietic
growth factors with comparable mitogenic and di¡erentiation
capacities, did not stimulate VEGF release. A simple interpre-
tation of these results is that the release of VEGF stimulated
by TPO is an integral feature of the process of megakaryo-
cytic di¡erentiation which is induced by this haematopoietic
factor. This interpretation would be consistent with the ¢nd-
ing that in UT-7/mpl cells EPO was unable to induce VEGF
release to a signi¢cant degree, in spite of the fact that it shares
with TPO a very similar intracellular signal transduction ma-
chinery [34].
Although induction of VEGF mRNA expression in CD34
cell cultures could be detected by the sensitive PCR within 24
h of incubation with TPO (Fig. 3), VEGF protein release, as
detected by ELISA, was not observed until 6^8 days of cul-
ture (Fig. 4). Since MKs are not seen in these cultures earlier
than day 4 [35], it could be argued that while VEGF mRNA
might be up-regulated in MK progenitors, VEGF protein
might be released only from cells that have undergone further
megakaryocytic maturation, or from mature MKs proper.
However, since the VEGF mRNA species detected by PCR
in this work correspond to those isoforms that are promptly
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Fig. 6. Stimulation of VEGF release by TPO in CD61 cells.
CD61 cells were puri¢ed by magnetic immunoselection and plated
at 6U105 cells/ml. The cells were incubated in absence (none) or
presence of 20 ng/ml TPO for 3 days. The amount of VEGF re-
leased into the medium was determined as described in Section 2.
Fig. 5. Comparison of the e¡ect of TPO, EPO and GM-CSF on the
stimulation of VEGF release in CD34 progenitor cell cultures.
CD34 cells were plated at 1.5U105 cells/ml and cultured for 9 days
with 20 or 40 ng/ml TPO, 2 ng/ml GM-CSF or 2 U/ml EPO, as in-
dicated. Cell number, percentage of CD61 cells and the amount of
VEGF released into the medium were determined as described in
Section 2. Results represent the mean þ S.E. of two experiments.
*P6 0.05; **P6 0.01.
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secreted in other cell types [11], it is worth considering
whether VEGF protein may have been released earlier than
we could detect it. CD34 cells constitute a heterogeneous
population enriched in primitive and committed progenitors
for all hematopoietic lineages. Vainchenker and his colleagues
have previously shown that only a small subset of these cells
(less than 2%) express c-Mpl [35]. A majority of CD34 c-
Mpl cells also expresses low levels of CD61, indicating that
they are late progenitors, already committed to the megakar-
yocytic lineage. In the presence of TPO, CD34 c-Mpl cells
undergo mitotic ampli¢cation and, along with this, further
megakaryocytic maturation [35]. Hence, because the number
of late MK progenitors initially present in these cultures is
very small, the less sensitive VEGF ELISA may not detect
the presence of this factor in the supernatant before this sub-
set has expanded substantially; this expansion would then
enable su⁄cient VEGF accumulation to occur. Taken togeth-
er, this suggests that TPO stimulates the release of VEGF at
least from the late MK progenitor stage onwards.
In histological sections of bone marrow MKs are often
found in intimate contact with the abluminal surface of sinus-
oidal endothelial cells. Theories of platelet production have
implicated either the passage of entire MKs through the sinus-
oidal endothelium or the projection (and subsequent fragmen-
tation) of MK cytoplasmic processes (proplatelets) into the
circulation [36]. Whatever the actual mechanism of platelet
release, our ¢ndings raise the possibility that VEGF produced
in response to TPO by di¡erentiating MKs, could act as a
paracrine factor on bone marrow microvascular endothelium
to facilitate the migration and release of platelets into the
circulation. This possibility would be entirely consistent with
the already documented role of VEGF as a mediator of trans-
endothelial migration for other cell types [3].
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